Replies to post #212973 on Biotech Values

[reaper247]

Hey Dew,

3 weeks, give or take for FINRA to post internal system changes.

Not sure what the new AEPP ticker will be.

From there, we are expecting OTCQB tier to be re-instated, since the company has maintained their SEC filing requirements.

The CEO stated in an interview that he intends to have Oncolix trading on the NASDAQ. He also stated in filing that they don't have any plans to do a reverse split.

So we have multiple forward looking events moving forward.

FINRA system change and then OTCQB tier. After that we are expecting to see the S-1 and S-1As to start hitting,

Could take a year for the eventual certnas filing, but hopefully by then the PPS will meet minimum listing requirements without a R/S.

I will post a AEPP/Oncolix summary that has the CEO interview.

Thanks for the response.

GLTU and the board.

IMO and FWIW.

[reaper247]

AEPP/Oncolix summary.

AEPP and Oncolix CEO Michael Redman discusses Oncolix, the progress of its Cancer treatment drug Prolanta, as well as announcing the completion of the Share Purchase Agreement with AEPP that he intends to use to take Oncolix public from April 24, 2017.

He also states his ambition to eventually have Oncolix listed on the NASDAQ.

He mentions the experienced Oncolix team.

The biographies of Oncolix officers, Board of Directors and company advisors have been released to the public and are available on the company website.

AEPP The Oncolix Team.

Management




Board Members






Company Advisors






Oncolix has a worldwide patent portfolio that is also available to view on the Oncolix website.



Leveraging these worldwide patents, Oncolix could be in a position to realize substantial gains in revenue and market capitalization.


Oncolix has completed several rounds of private offerings that are only available to accredited investors, family trusts, endowments and institutional investors. The latest round of funding was initiated in February 2017.

Accredited investors to date include the Greenville Hospital System, the Texas Emerging Technology Fund and the Ernest Mario Family Trust among others.

Ernest Mario served as Chief Executive Officer of Glaxo Holdings, plc, based out of London, England, known today as GlaxoSmithKline NYSE:GSK.

Ernest Mario was also the Chairman and CEO of Alza Corporation, based in Palo Alto, CA, from 1993 until the company was purchased by Johnson & Johnson, Inc, NYSE: JNJ in 2001.


Accredited investment often differs from PIPE financing that can be toxic or dilutive to current shareholders.

With the latest round of private offerings currently being completed, AEPP could continue clinical trials without any need to dilute.

IMO and FWIW.